Publications by authors named "Igor Grachev"

Claim this Profile
A
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.
Andrew McGarry, Peggy Auinger, Karl Kieburtz, Michal Geva, Munish Mehra, Igor D Grachev

J Huntingtons Dis· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [F] fluspidine and [F] fallypride PET study.
Igor D Grachev, Philipp M Meyer, Georg A Becker, Marcus Bronzel, Doug Marsteller

Eur J Nucl Med Mol Imaging· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices.
Mark Forrest Gordon, Igor D Grachev, Itzik Mazeh, Yonatan Dolan, Ralf Reilmann

Digit Biomark· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
Ralf Reilmann, Andrew McGarry, Igor D Grachev, Juha-Matti Savola, Beth Borowsky

Lancet Neurol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease.
Shani Cohen, Zeev Waks, Jordan J Elm, Mark Forrest Gordon, Igor D Grachev

BMC Med Inform Decis Mak· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
Frank Schneider, Lavi Erisson, Hooman Beygi, Margaret Bradbury, Orit Cohen-Barak, Igor D Grachev

Br J Clin Pharmacol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
Andrew McGarry, Karl Kieburtz, Victor Abler, Igor D Grachev, Sanjay Gandhi

J Huntingtons Dis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.
Craig Curtis, Jose E Gamez, Upinder Singh, Carl H Sadowsky, Teresa Villena, Igor D Grachev

JAMA Neurol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective flutemetamol positron emission tomography and histopathology in normal pressure hydrocephalus.
Juha O Rinne, Janek Frantzen, Ville Leinonen, Kimmo Lonnrot, Aki Laakso, Igor D Grachev

Neurodegener Dis· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes.
Nin Bajaj, Robert A Hauser, John Seibyl, Andreas Kupsch, Michail Plotkin, Igor D Grachev

Alzheimers Res Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging.
John P Seibyl, Andreas Kupsch, Jan Booij, Donald G Grosset, Durval C Costa, Igor D Grachev

J Nucl Med· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety analysis of 10 clinical trials and for 13 years after first approval of ioflupane 123I injection (DaTscan).
Donald G Grosset, Klaus Tatsch, Wolfgang H Oertel, Eduardo Tolosa, Nin Bajaj, Igor D Grachev

J Nucl Med· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials.
John T O'Brien, Wolfgang H Oertel, Ian G McKeith, Donald G Grosset, Zuzana Walker, Igor D Grachev

BMJ Open· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus.
Ville Leinonen, Juha O Rinne, Dean F Wong, David A Wolk, John Q Trojanowski, Igor D Grachev

Acta Neuropathol Commun· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan™).
Jeffrey L Cummings, Michael J Fine, Igor D Grachev, C Rick Jarecke, Meridith K Johnson

Am J Manag Care· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson's disease with depressive symptoms: a biological marker for causal relationships?
Igor D Grachev

J Neurol Neurosurg Psychiatry· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.
Nin Bajaj, Robert A Hauser, Igor D Grachev

J Neurol Neurosurg Psychiatry· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients.
Dean F Wong, Abhay R Moghekar, Daniele Rigamonti, James R Brašić, Olivier Rousset, Igor D Grachev

Mol Imaging Biol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in clinical management and diagnosis following DaTscan SPECT imaging in patients with clinically uncertain parkinsonian syndromes: a 12-week follow-up study.
Andreas Kupsch, Nin Bajaj, Frederick Weiland, Antonio Tartaglione, Susanne Klutmann, Igor D Grachev

Neurodegener Dis· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
Juha O Rinne, Dean F Wong, David A Wolk, Ville Leinonen, Steven E Arnold, Igor D Grachev

Acta Neuropathol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effects of a high-fat meal on the oral bioavailability of a single dose of preladenant in healthy subjects.
David L Cutler, Amol Tendolkar, Igor D Grachev

J Clin Pharmacol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study.
Andreas R Kupsch, Nin Bajaj, Frederick Weiland, Antonio Tartaglione, Susanne Klutmann, Igor D Grachev

J Neurol Neurosurg Psychiatry· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.
Johannes R Streffer, Igor D Grachev, Cheryl Fitzer-Attas, Baltazar Gomez-Mancilla, Babak Boroojerdi

Mov Disord· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo.
Koen Van Laere, Cindy Casteels, Sophie Lunskens, Karolien Goffin, Igor D Grachev

Neurobiol Aging· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.
David A Wolk, Igor D Grachev, Chris Buckley, Hala Kazi, M Sean Grady

Arch Neurol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis